

# CONTENTS

	<b>The Platinum Hall of Fame</b>	<b>e85</b>
	10.1016/j.eururo.2019.02.006	
Platinum Opinions	<b>On Having Grey Hair</b>	<b>541</b>
	<i>Francesco Montorsi</i>	
	Urologists should be aware of the importance of staying updated with the latest advances in medical research, chasing complications after surgery, being aware of postoperative results, building up a multidisciplinary team, and designing randomised trials for relevant research questions. Taken together, these key elements would allow for optimisation of patients' outcomes in everyday clinical practice.	
	<b>Evolving Changes in the Delivery of Health Services: A Place for Urological Homecare?</b>	<b>543</b>
	<i>K.A. Rumaihi, S.A. Boorjian, M. Jewett</i>	
	The ongoing pressure to improve quality while reducing costs is leading to increased uptake of various urological homecare models. Urological homecare can involve reductions in hospital usage and costs, traveling time for the patient, and hospital deaths and can improve patient experience and satisfaction.	
	<b>A Return to the Days of Radical Nephrectomy as the "Gold Standard" for Localized Renal Cell Carcinoma? Not So Fast</b>	<b>546</b>
	<i>I.H. Derweesh, M. Staehler, R.G. Uzzo</i>	
	Recent work by Gershman and colleagues adds to collective data favoring partial nephrectomy to optimize functional preservation while maintaining oncological equipoise in the management of T1 renal cancer, and should not be over-interpreted as an endorsement to preferentially perform radical nephrectomy.	
Brief Correspondence	<b>Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?</b>	<b>548</b>
	<i>F. Lohaus, K. Zöphel, S. Löck, M. Wirth, J. Kotzerke, M. Krause, M. Baumann, E.G.C. Troost, T. Hölscher</i>	
	Prostate-specific membrane antigen positron emission tomography (PSMA-PET) may identify patients with castration-resistant prostate cancer who benefit from metastasis-directed ablative radiotherapy. Median time to prostate-specific antigen progression after local ablative radiotherapy to one to three PET-positive lead metastases was 1.5 yr while continuing androgen deprivation. A prospective trial is ongoing.	
Platinum Priorities	<b>Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer</b>	<b>552</b>
	<i>S. Berg, A.P. Cole, M.J. Krimphove, J. Nabi, M. Marchese, S.R. Lipsitz, J. Noldus, T.K. Choueiri, A.S. Kibel, Q.-D. Trinh</i>	
Brief Correspondence, Original Articles and Review Articles together with the Full Length Editorials	In an analysis restricted to young and healthy men presenting with high-risk localized prostate cancer, initial radical prostatectomy is associated with an overall survival benefit compared with external beam radiation therapy plus brachytherapy.	<b>556</b>
Prostate Cancer	<b>Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?</b>	
	<i>P. Sooriakumaran, N. Pavan, P.N. Wiklund, M. Roach 3rd</i>	

**A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings** EU★ACME 558

*P.K.-F. Chiu, C.-F. Ng, A. Semjonow, Y. Zhu, S. Vincendeau, A. Houlgatte, M. Lazzeri, G. Guazzoni, C. Stephan, A. Haese, I. Bruijine, J.Y.-C. Teoh, C.H. Leung, P. Casale, C.H. Chiang, L.G.-L. Tan, E. Chiong, C.Y. Huang, H.C. Wu, D. Nieboer, D.-W. Ye, C.H. Bangma, M.J. Roobol*

The Prostate Health Index (PHI) test is effective in cancer risk stratification for both European and Asian men. A higher proportion of biopsies could be avoided among Asian men using PHI. An ethnic-specific reference range should be used.

**Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men** 562

*A.R. Zlotta, C. Kuk*

**Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube** 564

*S. Loeb, S. Sengupta, M. Butaney, J.N. Macaluso Jr., S.W. Czarniecki, R. Robbins, R.S. Braithwaite, L. Gao, N. Byrne, D. Walter, A. Langford*

Many of the top YouTube videos on prostate cancer contain biased or misinformative content. User engagement was higher for videos with a lower quality of information. Prostate cancer providers, researchers, and organizations should continue to create evidence-based content that is of interest to viewers to help balance what patients and their families access.

**Prostate Cancer Social Media: In YouTube We Trust?** 568

*B. Carneiro, D.S. Dizon*

**Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study** EU★ACME 570

*M. van der Leest, E. Cornel, B. Israël, R. Hendriks, A.R. Padhani, M. Hoogenboom, P. Zamecnik, D. Bakker, A.Y. Setiasti, J. Veltman, H. van den Hout, H. van der Lelij, I. van Oort, S. Klaver, F. Debruyne, M. Sedelaar, G. Hannink, M. Rovers, C. Hulsbergen-van de Kaa, J.O. Barentsz*

In biopsy-naïve patients, a magnetic resonance imaging (MRI) pathway compared with a transrectal ultrasound-guided biopsy pathway significantly reduces the detection rate of insignificant prostate cancer without impairing the detection rate of clinically significant prostate cancer. There is a potential to reduce the number of men requiring biopsy after nonsuspicious MRI to half, with an acceptable underdetection rate of 4%.

**In-bore Multiparametric Magnetic Resonance Imaging Targeted Biopsy: As Good as it Gets?** 579

*D.J. Rosario, T.J. Walton, S.J. Kennish*

**The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies** 582

*O. Wegelin, L. Exterkate, M. van der Leest, J.A. Kummer, W. Vreuls, P.C. de Bruin, J.L.H.R. Bosch, J.O. Barentsz, D.M. Somford, H.H.E. van Melick*

In a repeat biopsy setting, multiparametric magnetic resonance imaging (mpMRI)-based targeted biopsy has a high detection rate of (clinically significant) prostate cancer. There were no significant differences in the detection rates of (clinically significant) prostate cancer among three techniques of mpMRI-based targeted biopsy.

**Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial** 591

*T.Y. Sadun, R.E. Reiter*

Bladder Cancer



**BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)** 593

*J.D. Kelly, W.S. Tan, N. Porta, H. Mostafid, R. Huddart, A. Protheroe, R. Bogle, J. Blazeby, A. Palmer, J. Cresswell, M. Johnson, R. Brough, S. Madaan, S. Andrews, C. Cruickshank, S. Burnett, L. Maynard, E. Hall, on behalf of the BOXIT Investigators*

Celecoxib did not reduce the overall risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer. Subgroup analysis reported that time to recurrence was significantly longer in pT1 patients treated with celecoxib, although cardiovascular events were higher.

**Can We Prevent Bladder Cancer Recurrences?** 602

*J.L. Gore, J.L. Wright*

**Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial**  604

*J.E. Gschwend, M.M. Heck, J. Lehmann, H. Rübber, P. Albers, J.M. Wolff, D. Frohneberg, P. de Geeter, A. Heidenreich, T. Kälble, M. Stöckle, T. Schnöller, A. Stenzl, M. Müller, M. Truss, S. Roth, U.-B. Liehr, J. Leiner, T. Breggenzer, M. Retz*

In this randomized phase-III trial, extended lymph node dissection (LND) failed to show a statistically significant therapeutic advantage over limited LND in bladder cancer patients undergoing radical cystectomy. The benefit from extended LND in the primary endpoint recurrence-free survival was smaller than expected.

**What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?** 612

*S.P. Lerner, R.S. Svatek*

Sexual Medicine



**Benefits of Empiric Nutritional and Medical Therapy for Semen Parameters and Pregnancy and Live Birth Rates in Couples with Idiopathic Infertility: A Systematic Review and Meta-analysis** 615

*M.I. Omar, R.P. Pal, B.D. Kelly, H.M. Bruins, Y. Yuan, T. Diemer, C. Krausz, H. Tournaye, Z. Kopa, A. Jungwirth, S. Minhas*

This systematic review indicates that medical treatment and nutritional supplementation may improve male fertility. There is some evidence that empiric therapy may lead to improved rates of live birth, spontaneous pregnancy, and pregnancy following assisted reproductive techniques.

**Empiric Medical and Nutritional Therapy for Idiopathic Male Infertility: How Good Is the Evidence for What Works and Does Not?** 626

*J.Y. Clark*

Statistics in Urology



**Variability in Partial Nephrectomy Outcomes: Does Your Surgeon Matter?** 628

*J. Dagenais, R. Bertolo, J. Garisto, M.J. Maurice, P. Mouracade, O. Kara, J. Chavali, J. Li, R. Nelson, A. Fergany, R. Abouassaly, J.H. Kaouk*

There is significant between-surgeon variability in outcomes after partial nephrectomy, even after adjusting for patient characteristics. While renal functional outcomes are consistent across surgeons, measured and unmeasured surgeon factors account for 20–100% of the variability for the remaining peri- and postoperative variables. This has important implications for the goal of optimizing patient care with the increasing utilization of value-based medicine.

**Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care** 635

*P. Pierorazio, S. Eggener*

From Lab to Clinic	<p><b>The Microbiome and Genitourinary Cancer: A Collaborative Review</b> 637</p> <p><i>M.C. Markowski, S.A. Boorjian, J.P. Burton, N.M. Hahn, M.A. Ingersoll, S.M. Vareki, S.K. Pal, K.S. Sfanos</i></p> <p>There is evidence that the urinary microbiome influences the development of genitourinary malignancies, including bladder, kidney, and prostate cancers. Furthermore, the gastrointestinal microbiota may also influence genitourinary cancer development and/or treatment response via effects on drug metabolism and systemic immunity.</p> <p><b>The Microbiome: Another Dimension in the Pathophysiology of Urogenital Disease</b> 647</p> <p><i>D.A.W. Janssen</i></p>
Reviews	<p><b>Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes</b> 649</p> <p><i>M. Abufaraj, B. Foerster, E. Schernhammer, M. Moschini, S. Kimura, M.R. Hassler, M.A. Preston, P.I. Karakiewicz, M. Remzi, S.F. Shariat</i></p> <p>Micropapillary urothelial carcinoma is associated with advanced pathological features but not necessarily worse outcomes. Accordingly, it does not necessarily mandate different treatment options. Nevertheless, each case should be discussed individually in a multidisciplinary approach.</p>
Urothelial Cancer	<p><b><sup>99m</sup>Tc-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer</b> 659</p> <p><i>T. Maurer, S. Robu, M. Schottelius, K. Schwamborn, I. Rauscher, N.S. van den Berg, F.W.B. van Leeuwen, B. Haller, T. Horn, M.M. Heck, J.E. Gschwend, M. Schwaiger, H.-J. Wester, M. Eiber</i></p> <p><sup>99m</sup>Tc-based prostate-specific membrane antigen–radioguided surgery as a new surgical technique is feasible, and has been proved to be of high value for successful intraoperative detection and removal of metastatic lesions in prostate cancer patients scheduled for salvage surgery. Its long-term impact on outcome has to be evaluated.</p>
Surgery in Motion	<p><b>Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer</b> 667</p> <p><i>G. Vandekerkhove, W.J. Struss, M. Annala, H.M.L. Kallio, D. Khalaf, E.W. Warner, C. Herberths, E. Ritch, K. Beja, Y. Loktionova, A. Hurtado-Coll, L. Fazli, A. So, P.C. Black, M. Nykter, T. Tammela, K.N. Chi, M.E. Gleave, A.W. Wyatt</i></p> <p>Circulating tumor DNA (ctDNA) is highly abundant in de novo metastatic prostate cancer, but short-term androgen deprivation therapy rapidly reduces ctDNA. The best approach for tumor molecular subtyping and precision oncology should utilize both primary tissue biopsy and ctDNA.</p>
Original Articles	<p><b>Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer</b> 676</p> <p><i>K. Beckmann, H. Garmo, J. Adolfsson, C. Bosco, E. Johansson, D. Robinson, L. Holmberg, P. Stattin, M. Van Hemelrijck</i></p> <p>The increase in overall comorbidity following androgen androgen deprivation therapy for advanced prostate cancer was significantly higher for gonadotrophin gonadotrophin-releasing hormone agonists than for antiandrogen (AA) monotherapy. More consideration should be given to AA monotherapy as an alternative firstline therapy.</p>
Case Series of the Month	<p><b>Robotic Urologic Surgical Interventions Performed with the Single Port Dedicated Platform: First Clinical Investigation</b> 684</p> <p><i>J. Kaouk, J. Garisto, R. Bertolo</i></p>

Words of Wisdom



<b>Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE)</b>	<b>692</b>
<i>A. Kretschmer, M.E. Gleave</i>	
<b>Re: Long-term Rate of Mesh Sling Removal Following Midurethral Mesh Sling Insertion Among Women With Stress Urinary Incontinence</b>	<b>693</b>
<i>D.S. Hess, G.E. Lemack</i>	
<b>Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy</b>	<b>694</b>
<i>T.C.M. Zuiverloon, D. Theodorescu</i>	
<b>Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study</b>	<b>695</b>
<i>K.M. Gust, S.F. Shariat</i>	
<b>Re: Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Health Care Costs, 2003 to 2015</b>	<b>696</b>
<i>A.P. Cole, A.S. Kibel</i>	
<b>Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial</b>	<b>697</b>
<i>V. Grünwald, B. Hadaschik</i>	

Research Letters



<b>Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer</b>	<b>699</b>
<i>T.B.L. Lam, S. MacLennan, K. Plass, P.-P.M. Willemse, M.D. Mason, P. Cornford, J. Donaldson, N.F. Davis, P. Dell'Oglio, C. Fankhauser, N. Grivas, A. Ingels, M. Lardas, M. Liew, K.H. Pang, C. Paterson, M.I. Omar, F. Zattoni, K.T. Buddingh, T. Van den Broeck, M.G. Cumberbatch, N. Fossati, T. Gross, L. Moris, I.G. Schoots, R.C.N. van den Bergh, E. Briers, S. Fanti, M. De Santis, S. Gillissen, J.P. Grummet, A.M. Henry, H.G. van der Poel, T.H. van der Kwast, O. Rouvière, D. Tilki, T. Wiegel, J. N'Dow, H. Van Poppel, N. Mottet</i>	
<b>Prevalence of and Predictive Factors for Burnout Among French Urologists in Training</b>	<b>702</b>
<i>J. Gas, S. Bart, P. Michel, B. Peyronnet, S. Bergerat, J. Olivier, D. Gambachidze, W. Akakpo, C. Lebacle, M. Nedelec, P. Panayotopoulos, M. Baron, E. Perrot, B. Gondran-Tellier, A. Manuguerra, I. Dominique, X. Matillon, B. Pradere, On behalf of the AFUF (Association Francaise des Urologues en Formation)</i>	

Letters to the Editor published online



<b>Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2019;75:319–28. Radiation Therapy Versus Radical Prostatectomy: No Way Out Without a Randomized Trial</b>	<b>e93</b>
<i>A. Fiorentino, A. Errico, M. Scarcia</i>	
<b>Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2019;75:319–28. Radiation Therapy Versus Radical Prostatectomy: No Way Out Without a Randomized Trial</b>	<b>e95</b>
<i>M. Moschini, E. Zaffuto, A. Mattei, P.I. Karakiewicz, S.F. Shariat</i>	
<b>Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2019;75:319–28.</b>	<b>e96</b>
<i>N.G. Zaorsky, D.E. Spratt, P. Blanchard</i>	

- Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2019;75:319–28.** e98  
*M. Moschini, E. Zaffuto, A. Mattei, P.I. Karakiewicz, S.F. Shariat*
- Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410–418. High-volume Disease Has a Different Standard of Care** e100  
*H.A. García-Perdomo*
- Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410–418. High-volume Disease Has a Different Standard of Care. Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?** e101  
*L.M.S. Boevé, A.N. Vis*
- Re: Henrik Grönberg, Martin Eklund, Wolfgang Pickler, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018;74:722–8.** e103  
*E. Rud, P. Lauritzen, E. Baco*
- Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Grönberg, Martin Eklund, Wolfgang Pickler, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018;74:722–8.** e104  
*M. Eklund, P. Ström, H. Grönberg, T. Nordström*
- Re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. 2019;75:423–432.** e106  
*P. Eriksson, G. Sjö Dahl*
- Reply to Pontus Eriksson and Gottfrid Sjö Dahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. 2019;75:423–432.** e108  
*T.Z. Tan, M. Rouanne, R.Y.-J. Huang, J.-P. Thiery*
- Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6. Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization?** e110  
*A. Cimadamore, M. Scarpelli, M. Santoni, L. Cheng, A. Lopez-Beltran, F. Montorsi, R. Montironi*
- Re: Stephanie Guillaumier, Max Peters, Manit Arya, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 2018;74:422–9** e114  
*Z. Zhou, Y. Zhou, W. Yan*

Corrigendum



Congress Calendar

e115

Corrigendum re “Prospective Randomised Controlled Trial of Transobturator Tapes in Management of Urodynamic Stress Incontinence in Women: 3-Year Outcomes from the Evaluation of Transobturator Tapes Study” [Eur Urol 2012;62:843–51]

e119

*M. Abdel-fattah, A. Mostafa, A. Familusi, I. Ramsay, J. N'Dow*

The illustration on the cover of this issue is taken from the article by Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, Herbert Rübber, Peter Albers, Johannes M. Wolff, Detlef Frohneberg, Patrick de Geeter, Axel Heidenreich, Tilman Kälble, Michael Stöckle, Thomas Schnöller, Arnulf Stenzl, Markus Müller, Michael Truss, Stephan Roth, Uwe-Bernd Liehr, Joachim Leibner, Thomas Bregenzer, Margitta Retz, Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial, which is published on pp. 604–611 of this issue.

